The "Lyme Disease (LD): Market View" report has been added to ResearchAndMarkets.com's offering.

This reports provides a data-driven overview of the current and future competitive landscape in LD Therapeutics.

In 2024 and 2029, Germany is anticipated to have the highest number of incident cases of Lyme disease, representing a large portion of global cases.

Currently, the Lyme disease market is saturated with generic drugs, and the penicillin-binding protein (PBP) inhibitor drug class dominates the approved innovator drugs currently available to treat Lyme disease. The Lyme disease pipeline holds 23 molecules, with no asset in the pre-registration stage, one asset in Phase III, and another three assets in Phase II.

Over the past decade, 63 clinical trials have been conducted in Lyme disease. The year with the most studies initiated was 2021, followed by 2022 with nine trials and 2018 with eight trials. During the past 26 months, four mergers and acquisitions and three strategic alliances involving companies developing Lyme disease assets were completed globally.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the LD Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global LD Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Molecule Type

4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

5.1 Annual Cost of Therapy

5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

6.1 Mid-to-late-stage Pipeline Drugs

6.2 Overview by Development Stage

6.3 Overview by Mechanism of Action

6.4 Overview by Molecule Type

6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

7.1 Historical Overview

7.2 Overview by Phase

7.3 Overview by Status

7.4 Overview by Phase for Ongoing and Planned Trials

7.5 Trials with Virtual Components

7.6 Overview of Trials by Geography

7.7 Single-Country and Multinational Trials by Region

7.8 Top 20 Sponsors with Breakdown by Phase

7.9 Top 20 Sponsors with Breakdown by Status

7.10 Overview by Endpoint Status

7.11 Overview by Race and Ethnicity

7.12 Enrollment Data

7.13 Top 20 countries for Trial Sites

7.14 Top 20 Sites Globally

7.15 Feasibility Analysis - Geographic Overview

7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

8.1 Mergers, Acquisitions, and Strategic Alliances by Region

8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

11.1 Methodology

11.2 Methodology - Sales Forecast

11.3 Methodology - Pricing and Reimbursement

11.4 Methodology - PTSR and LoA Analysis

For more information about this report visit https://www.researchandmarkets.com/r/s0t0ys

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203869360/en/